mRNA 합성 원료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

mRNA Synthesis Raw Materials Market Summary

The global mRNA synthesis raw materials market size was estimated at USD 1.73 billion in 2025 and is projected to reach USD 2.93 billion by 2033, growing at a CAGR of 7.10% from 2026 to 2033. The growing mRNA vaccine and therapeutic pipeline, higher investments in cell and gene therapy R&D, The increasing need for high-quality synthesis reagents, and the expansion of GMP-compliant manufacturing by biotechnology and pharmaceutical companies are the main drivers of this growth.

Global mRNA Synthesis Raw Materials Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the mRNA synthesis raw materials market on the basis of type, application, end user, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Capping Agents
• Nucleotides
  • Modified Nucleic Acids
  • N1-methylpseudouridine-triphosphate
  • 5-Methylcytidine triphosphate (5mCTP)
  • Natural Nucleic Acids
  • Adenine
  • Guanine
  • Cytosine
  • Uracil
• Plasmid DNA
• Enzymes
  • Polymerase
  • RNase Inhibitor
  • DNase
  • Others
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Vaccine Production
• Therapeutics Production
• Others
• End use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global mRNA Synthesis Raw Materials Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growth of mRNA Vaccines and Therapeutics
    • 3.2.1.2. Technological Improvements in mRNA Synthesis Technology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Complex Regulatory Requirements
• 3.3. mRNA Synthesis Raw Materials Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global mRNA Synthesis Raw Materials Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Global mRNA Synthesis Raw Materials Market Type Movement Analysis
• 4.3. Global mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Capping Agents
  • 4.4.1. Capping agents market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Nucleotides
  • 4.5.1. Nucleotides market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. Modified nucleic acids
    • 4.5.2.1. Modified nucleic acids market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2.2. N1-methylpseudouridine-triphosphate
      • 4.5.2.2.1. N1-methylpseudouridine-triphosphate market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2.3. 5-Methylcytidine triphosphate (5mCTP)
      • 4.5.2.3.1. 5-Methylcytidine triphosphate (5mCTP) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2.4. Others
      • 4.5.2.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.3. Natural nucleic acids
    • 4.5.3.1. Natural nucleic acids market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.2. Adenine
      • 4.5.3.2.1. Adenine-triphosphate market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.3. Guanine
      • 4.5.3.3.1. Guanine market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.4. Cytosine
      • 4.5.3.4.1. Cytosine market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3.5. Uracil
      • 4.5.3.5.1. Uracil market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Plasmid DNA
  • 4.6.1. Plasmid DNA market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Enzymes market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7.2. Polymerase
    • 4.7.2.1. Polymerase market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7.3. RNase Inhibitor
    • 4.7.3.1. RNase inhibitor market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7.4. DNase
    • 4.7.4.1. DNase market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global mRNA Synthesis Raw Materials Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global mRNA Synthesis Raw Materials Market Application Movement Analysis
• 5.3. Global mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Vaccine Production
  • 5.4.1. Vaccine production market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Therapeutics Production
  • 5.5.1. Therapeutics production market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global mRNA Synthesis Raw Materials Market: End use Estimates & Trend Analysis

• 6.1. End use Segment Dashboard
• 6.2. Global mRNA Synthesis Raw Materials Market End use Movement Analysis
• 6.3. Global mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 6.4. Biopharmaceutical & Pharmaceutical Companies
  • 6.4.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. CROs & CMOs
  • 6.5.1. CROs & CMOs market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Academic & Research Institutes
  • 6.6.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. mRNA Synthesis Raw Materials Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait mRNA Synthesis Raw Materials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. F. Hoffmann - La Roche Ltd.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Jena Bioscience Gmbh
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Merck KGaA
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. BOC Sciences
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Thermo Fisher Scientific, Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Maravai Lifesciences
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. New England Biolabs
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Creative Biogene
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Hongene
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives